Similar Items: Anti‐amyloid nanobody‐Fc fusion protein drives potent amyloid clearance through microglial recruitment
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial
- Eligibility for anti‐amyloid treatment in a multiethnic community‐based study
- White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
- Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- Anti‐amyloid therapy eligibility in a longitudinal brain‐donor cohort with post mortem confirmation